030702

COPY OF I

0120

Docket No.: PA-0028 US

I hereby certify this construction on the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on January 14, 2002

By: Printed:

Debbie Ellis

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Olga Bandman

Title:

GENES DIFFERENTIALLY EXPRESSED IN VASCULAR TISSUE

ACTIVATION

Serial No.:

To Be Assigned (0/044, 590) Filing Date:

January 8, 2002

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

89897

1

Docket No.: PA-0028 US

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 14, 2012

Lynn E. Murry, Ph.D.

Reg. No. 42,918

Direct Dial Telephone: (650) 845-4159

3160 Porter Drive

Palo Alto, California 94304

Phone: (650) 855-0555 Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office					Atty Docket No.		Serial No.	
					PA-0028 US		To Be Assigned	
LIST OF REFERENCES CITED BY APPLICANTS					Applicant(s)			
F Wse several sheets if necessary)					Bandman			
(0, co.)					Filing Date		Group	
FEB 0 4 2002 (2)					January 8, 2002		To Be Assigned	
U.S. Patent Documents								
*Examiner	TALL	Document					Filing Date	
Initial		Number	Date	Name	Class	Subclass	If Appropriate	
Foreign Patent Documents								
	·						Trans:	lation
		Document	Date	Country	Class	Subclass	Yes	No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
	Horrevoets, A.J.G. et al., "Vascular Endothelial Genes That Are Responsive to Tumor Necrosis Factor-α In Vitro Are Expressed in Atherosclerotic Lesions, Including Inhibitor of Apoptosis Protein-1, Stannin, and Two Novel Genes", Blood, 93:3418-3431 (1999)							
	2	de Vries, C.J.M. et al., "Differential Display Identification of 40 Genes with Altered Expression in Activated Human Smooth Muscle Cells", <u>J. Biol. Chem.</u> , 275:23939-23947 (2000)						
	3	Heller, R.A. et al., "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays", Proc. Natl. Acad. Sci. USA , 94:2150-2155 (1997)						
	4	Haley, K.J. et al., "Overexpression of Eotaxin and the CCR3 Receptor in Human Atherosclerosis", <u>Circulation</u> , 102:2185-2189 (2000)						
								
						· · · · · · · · · · · · · · · · · · ·	•	
								
Examiner			Date Considered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include conve								

of this form with your communication to applicant.